Food & Drug Administration (FDA) FDA grants accelerated approval to elamipretide (Forzinity) as first treatment for Barth syndrome (2025) Journal of the American College of Cardiology (JACC) PROGRESSHF trial: safety and tolerability of elamipretide in heart failure patients Neurology (AAN Journals) MMPOWER2 trial: elamipretide in primary mitochondrial myopathy Genetics in Medicine (Nature) TAZPOWER trial: efficacy and safety of elamipretide in Barth syndrome Biochimica et Biophysica Acta (BBA) Bioenergetics Cardiolipin remodeling and cristae structure: role in mitochondrial function Journal of Cardiovascular Pharmacology (PMC) SS31 reduces oxidative stress and improves mitochondrial bioenergetics Alzheimers Drug Discovery Foundation Cognitive Vitality Report: SS31 (elamipretide) preclinical and clinical overview Orphanet Journal of Rare Diseases (PMC) Barth syndrome: clinical presentation, diagnosis, and emerging therapies Research Resources BPC-157 (5 mg & 10 mg Vial) Dosage Protocol Quickstart Highlights BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide derived from a gastric protein sequence studied for tissue-healing and cytoprotective properties [1] [2]
If osteoarthritis is relevant to your situation, this should be part of the conversation with your physician before starting any protocol
National Library of Medicine) Get the free Peptide Skincare Guide A simple, free PDF: what peptides do, which ones are worth your money, and how to read a label without getting fooled
ABC transporters (ATP-binding cassette) specially P-gp (P-glycoprotein) play an important role in clinical drug resistance by many of mechanisms for example high level expression by gene rearrangement
Technologies like nanoparticle encapsulation, enteric coatings, and permeation enhancers are advancing rapidly
Some users enjoy this effect
